These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10480630)

  • 21. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
    HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression.
    Bailer RT; Holloway A; Sun J; Margolick JB; Martin M; Kostman J; Montaner LJ
    J Immunol; 1999 Jun; 162(12):7534-42. PubMed ID: 10358209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Bourgeois A; Laurent C; Mougnutou R; Nkoué N; Lactuock B; Ciaffi L; Liégeois F; Andrieux-Meyer I; Zekeng L; Calmy A; Mpoudi-Ngolé E; Delaporte E
    Antivir Ther; 2005; 10(2):335-41. PubMed ID: 15865228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
    Connick E; Lederman MM; Kotzin BL; Spritzler J; Kuritzkes DR; St Clair M; Sevin AD; Fox L; Chiozzi MH; Leonard JM; Rousseau F; D'Arc Roe J; Martinez A; Kessler H; Landay A
    J Infect Dis; 2000 Jan; 181(1):358-63. PubMed ID: 10608789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
    J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy.
    Imami N; Hardy GA; Nelson MR; Morris-Jones S; Al-Shahi R; Antonopoulos C; Gazzard B; Gotch FM
    Clin Exp Immunol; 1999 Oct; 118(1):78-86. PubMed ID: 10540163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of specific T-cell responses in HIV infection.
    Leandersson AC; Bratt G; Hinkula J; Gilljam G; Cochaux P; Samson M; Sandström E; Wahren B
    AIDS; 1998 Jan; 12(2):157-66. PubMed ID: 9468364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV).
    Raise E; Guerra L; Viza D; Pizza G; De Vinci C; Schiattone ML; Rocaccio L; Cicognani M; Gritti F
    Biotherapy; 1996; 9(1-3):49-54. PubMed ID: 8993757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.
    Prins JM; Jurriaans S; van Praag RM; Blaak H; van Rij R; Schellekens PT; ten Berge IJ; Yong SL; Fox CH; Roos MT; de Wolf F; Goudsmit J; Schuitemaker H; Lange JM
    AIDS; 1999 Dec; 13(17):2405-10. PubMed ID: 10597782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus.
    Haslett P; Hempstead M; Seidman C; Diakun J; Vasquez D; Freedman VH; Kaplan G
    AIDS Res Hum Retroviruses; 1997 Aug; 13(12):1047-54. PubMed ID: 9264292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART.
    Aandahl EM; Aukrust P; Müller F; Hansson V; Taskén K; Frøland SS
    AIDS; 1999 Dec; 13(17):F109-14. PubMed ID: 10597771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood.
    Shannon E; Aseffa A; Pankey G; Sandoval F; Lutz B
    Immunopharmacology; 2000 Feb; 46(2):175-9. PubMed ID: 10647875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines.
    Marriott JB; Cookson S; Carlin E; Youle M; Hawkins DA; Nelson M; Pearson M; Vaughan AN; Gazzard B; Dalgleish AG
    AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1625-31. PubMed ID: 9430254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide for the treatment of AIDS-associated wasting.
    Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PA; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1345-55. PubMed ID: 11018854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.
    Adalid-Peralta L; Godot V; Colin C; Krzysiek R; Tran T; Poignard P; Venet A; Hosmalin A; Lebon P; Rouzioux C; Chene G; Emilie D;
    J Leukoc Biol; 2008 Apr; 83(4):1060-7. PubMed ID: 18182457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro immunotoxicity of +/- 2'-deoxy-3'-thiacytidine, a new anti-HIV agent.
    Lisignoli G; Monaco MC; Degrassi A; Toneguzzi S; Ricchi E; Costigliola P; Facchini A
    Clin Exp Immunol; 1993 Jun; 92(3):455-9. PubMed ID: 8390335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART.
    Ramirez LA; Arango TA; Thompson E; Naji M; Tebas P; Boyer JD
    J Leukoc Biol; 2014 Dec; 96(6):1055-63. PubMed ID: 25157027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.